Dr. Scholz discusses the use of Abiraterone in mCRPC

Dr. Scholz discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Mark ... Author: onclivetv Added: 03/04/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts